Cargando…
Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients
Upregulation of Vimentin (VIM), alpha-Tubulin (TUB) and Detyrosinated tubulin (GLU) in circulating tumor cells (CTCs) derived from breast cancer patients is related to poor prognosis. In the current study we evaluated for the first time, these cytoskeletal proteins in sixty Non-Small Cell Lung Cance...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875112/ https://www.ncbi.nlm.nih.gov/pubmed/35207643 http://dx.doi.org/10.3390/jpm12020154 |
_version_ | 1784657839366602752 |
---|---|
author | Katsarou, Spyridoula D. Messaritakis, Ippokratis Voumvouraki, Anastasia Kakavogiannis, Stavros Κotsakis, Athanasios Alkahtani, Saad Stournaras, Christos Martin, Stuart S. Georgoulias, Vassilis Kallergi, Galatea |
author_facet | Katsarou, Spyridoula D. Messaritakis, Ippokratis Voumvouraki, Anastasia Kakavogiannis, Stavros Κotsakis, Athanasios Alkahtani, Saad Stournaras, Christos Martin, Stuart S. Georgoulias, Vassilis Kallergi, Galatea |
author_sort | Katsarou, Spyridoula D. |
collection | PubMed |
description | Upregulation of Vimentin (VIM), alpha-Tubulin (TUB) and Detyrosinated tubulin (GLU) in circulating tumor cells (CTCs) derived from breast cancer patients is related to poor prognosis. In the current study we evaluated for the first time, these cytoskeletal proteins in sixty Non-Small Cell Lung Cancer (NSCLC) patients’ CTCs (33 treatment-naïve and 27 pre-treated). Samples were isolated using the ISET platform and stained with a pancytokeratin (CK)/CD45/TUB, CK/GLU/VIM and CK/programmed death ligand 1 (PD-L1) combination of antibodies. Subsequently, slides were analyzed using confocal laser scanning microscopy. CTCs were detected in 86.7% of the patients. CTCs with TUB expression were identified in 65.4% (34/52) of the CK (+)-patients. GLU, VIM and PD-L1 were also evaluated. The frequency of the observed phenotypes was as follow: (CK+/GLU−/VIM−): 35.2%, (CK+/GLU+/VIM+): 63.0%, (CK+/GLU+/VIM−): 16.7%, (CK+/GLU−/VIM+): 72.2%, (CK+/PD-L1−): 75% and (CK+/PD-L1+): 55%. The OS was significantly decreased in patients with high GLU (3.8 vs. 7.9 months; p = 0.018) and/or high VIM (3.2 vs. 7.1 months; p = 0.029) expression in their CTCs. PD-L1 was also related to OS (3.4 vs. 7.21 months; p = 0.035). Moreover, TUB-high and TUB-low expression in CTCs inversely influenced patients’ OS as independent prognostic factors (p = 0.041 and p = 0.009). The current study revealed that TUB, GLU, VIM and PD-L1 were overexpressed in CTCs from NSCLC patients. Furthermore, the presence of GLU, VIM-positive and PD-L1 in CTCs is potentially related to patients’ outcomes. |
format | Online Article Text |
id | pubmed-8875112 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88751122022-02-26 Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients Katsarou, Spyridoula D. Messaritakis, Ippokratis Voumvouraki, Anastasia Kakavogiannis, Stavros Κotsakis, Athanasios Alkahtani, Saad Stournaras, Christos Martin, Stuart S. Georgoulias, Vassilis Kallergi, Galatea J Pers Med Article Upregulation of Vimentin (VIM), alpha-Tubulin (TUB) and Detyrosinated tubulin (GLU) in circulating tumor cells (CTCs) derived from breast cancer patients is related to poor prognosis. In the current study we evaluated for the first time, these cytoskeletal proteins in sixty Non-Small Cell Lung Cancer (NSCLC) patients’ CTCs (33 treatment-naïve and 27 pre-treated). Samples were isolated using the ISET platform and stained with a pancytokeratin (CK)/CD45/TUB, CK/GLU/VIM and CK/programmed death ligand 1 (PD-L1) combination of antibodies. Subsequently, slides were analyzed using confocal laser scanning microscopy. CTCs were detected in 86.7% of the patients. CTCs with TUB expression were identified in 65.4% (34/52) of the CK (+)-patients. GLU, VIM and PD-L1 were also evaluated. The frequency of the observed phenotypes was as follow: (CK+/GLU−/VIM−): 35.2%, (CK+/GLU+/VIM+): 63.0%, (CK+/GLU+/VIM−): 16.7%, (CK+/GLU−/VIM+): 72.2%, (CK+/PD-L1−): 75% and (CK+/PD-L1+): 55%. The OS was significantly decreased in patients with high GLU (3.8 vs. 7.9 months; p = 0.018) and/or high VIM (3.2 vs. 7.1 months; p = 0.029) expression in their CTCs. PD-L1 was also related to OS (3.4 vs. 7.21 months; p = 0.035). Moreover, TUB-high and TUB-low expression in CTCs inversely influenced patients’ OS as independent prognostic factors (p = 0.041 and p = 0.009). The current study revealed that TUB, GLU, VIM and PD-L1 were overexpressed in CTCs from NSCLC patients. Furthermore, the presence of GLU, VIM-positive and PD-L1 in CTCs is potentially related to patients’ outcomes. MDPI 2022-01-25 /pmc/articles/PMC8875112/ /pubmed/35207643 http://dx.doi.org/10.3390/jpm12020154 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Katsarou, Spyridoula D. Messaritakis, Ippokratis Voumvouraki, Anastasia Kakavogiannis, Stavros Κotsakis, Athanasios Alkahtani, Saad Stournaras, Christos Martin, Stuart S. Georgoulias, Vassilis Kallergi, Galatea Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients |
title | Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients |
title_full | Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients |
title_fullStr | Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients |
title_full_unstemmed | Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients |
title_short | Detyrosinated α-Tubulin, Vimentin and PD-L1 in Circulating Tumor Cells (CTCs) Isolated from Non-Small Cell Lung Cancer (NSCLC) Patients |
title_sort | detyrosinated α-tubulin, vimentin and pd-l1 in circulating tumor cells (ctcs) isolated from non-small cell lung cancer (nsclc) patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875112/ https://www.ncbi.nlm.nih.gov/pubmed/35207643 http://dx.doi.org/10.3390/jpm12020154 |
work_keys_str_mv | AT katsarouspyridoulad detyrosinatedatubulinvimentinandpdl1incirculatingtumorcellsctcsisolatedfromnonsmallcelllungcancernsclcpatients AT messaritakisippokratis detyrosinatedatubulinvimentinandpdl1incirculatingtumorcellsctcsisolatedfromnonsmallcelllungcancernsclcpatients AT voumvourakianastasia detyrosinatedatubulinvimentinandpdl1incirculatingtumorcellsctcsisolatedfromnonsmallcelllungcancernsclcpatients AT kakavogiannisstavros detyrosinatedatubulinvimentinandpdl1incirculatingtumorcellsctcsisolatedfromnonsmallcelllungcancernsclcpatients AT kotsakisathanasios detyrosinatedatubulinvimentinandpdl1incirculatingtumorcellsctcsisolatedfromnonsmallcelllungcancernsclcpatients AT alkahtanisaad detyrosinatedatubulinvimentinandpdl1incirculatingtumorcellsctcsisolatedfromnonsmallcelllungcancernsclcpatients AT stournaraschristos detyrosinatedatubulinvimentinandpdl1incirculatingtumorcellsctcsisolatedfromnonsmallcelllungcancernsclcpatients AT martinstuarts detyrosinatedatubulinvimentinandpdl1incirculatingtumorcellsctcsisolatedfromnonsmallcelllungcancernsclcpatients AT georgouliasvassilis detyrosinatedatubulinvimentinandpdl1incirculatingtumorcellsctcsisolatedfromnonsmallcelllungcancernsclcpatients AT kallergigalatea detyrosinatedatubulinvimentinandpdl1incirculatingtumorcellsctcsisolatedfromnonsmallcelllungcancernsclcpatients |